Pangen Biotech Inc
222110
Company Profile
Business description
Pangen Biotech Inc is a biotechnology company. The company is engaged in the production and sales of biosimilar EPO drugs, contract manufacturing (CMO), and development technology transfer service (CDO) business for biopharmaceuticals, including non-clinical and clinical samples, and biopharmaceutical development business.
Contact
306 Sinwon-ro, Yeongtong-gu
4th floor, Yeongtong Innoplex 2nd building, Woncheon-dong
Gyeonggi-do
Suwon-si
KORT: +82 317339165
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
75
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,058.00 | 53.00 | -0.58% |
| CAC 40 | 8,126.53 | 55.17 | 0.68% |
| DAX 40 | 24,538.81 | 229.35 | 0.94% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,223.54 | 51.78 | 0.51% |
| HKSE | 26,830.50 | 556.61 | -2.03% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 53,422.01 | 99.16 | 0.19% |
| NZX 50 Index | 13,399.08 | 24.10 | -0.18% |
| S&P 500 | 6,939.03 | 29.98 | -0.43% |
| S&P/ASX 200 | 8,766.70 | 54.40 | -0.62% |
| SSE Composite Index | 4,076.97 | 40.98 | -1.00% |